SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
New Delhi: The Atal Innovation Mission (AIM) under NITI Aayog on Thursday partnered with Hindustan Unilever Limited (HUL) to launch a nationwide start-up acceleration programme aimed at speeding up ...
A company that most people have never heard of is among the year’s best-performing technology firms—and a symbol of the complex, interconnected, and potentially catastrophic ways in which AI companies ...
Milan and Madrid are the top performers. Defense stocks and banks are dominating. Big Tech is sprinting on Wall Street, but Tesla ...
Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...
Brits are a patient bunch - wasting 3% of their entire lives waiting in queues. Researchers analysed the times we wait in queues for supermarkets, post offices, bus stops, sports events, car parks and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback